ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,164Medicare Part D Prescriptions Filled, Including Refills

Rank: 336 out of 1000

$355K Total Retail Price of All Prescriptions

Rank: 390 out of 1000

596 Patients Receiving at Least One Drug in Part D
70%Patients 65 Years and Older
45% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Alabama
Lower avg

Schedule Two
Controlled Substances

3% of this provider’s 596 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

34% of this provider’s 596 patients filled at least one prescription for a schedule three drug, compared to an average of 20%.

Risky Drugs to Seniors

2% of this provider’s 6,117 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

20% of this provider’s prescriptions were for brand-name drugs, compared to an average of 21%.

Prescription Price

$44 was the average price of a prescription from this provider, compared to $49 among peers.

Prescriptions per Patient

14 is the average number of prescriptions (including refills) per patient, compared to an average of 21.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Alabama
HYDROCODONE-ACETAMINOPHEN 813 551 S3 1 1
LISINOPRIL 247 190 2 5
ZOLPIDEM TARTRATE 246 192 3 16
SIMVASTATIN 220 169 4 3
OMEPRAZOLE 219 179 5 2
AMLODIPINE BESYLATE 218 196 6 6
MELOXICAM 202 137 7 14
FUROSEMIDE 193 150 8 7
LISINOPRIL-HYDROCHLOROTHIAZIDE 182 151 9 20
TRAMADOL HCL 168 111 10 13
LEVOTHYROXINE SODIUM 152 129 11 4
POTASSIUM CHLORIDE 147 127 12 10
METFORMIN HCL ER 137 116 13 44
METFORMIN HCL 131 116 14 8
CLONIDINE HCL 120 86 15 27
PRAVASTATIN SODIUM 120 93 15 12
ATORVASTATIN CALCIUM 113 97 17 18
PANTOPRAZOLE SODIUM 106 79 18 28
TAMSULOSIN HCL 105 104 19 33
CARVEDILOL 102 97 20 15
GABAPENTIN 101 52 21 11
GLIPIZIDE ER 98 94 22 106
CITALOPRAM HBR 96 68 23 17
FENOFIBRATE 87 59 24 55
HYDROCHLOROTHIAZIDE 81 56 25 9
TRILIPIX 79 67 26 218
CYCLOBENZAPRINE HCL 79 57 R 26 39
WARFARIN SODIUM 74 65 28 22
METOPROLOL SUCCINATE 69 50 29 21
AZITHROMYCIN 66 47 30 36
CLOPIDOGREL 65 65 31 35
CRESTOR 56 36 32 30
METOPROLOL TARTRATE 55 46 33 19
ATENOLOL 55 50 33 24
TRAZODONE HCL 53 44 35 29
TRIAMTERENE-HCTZ 53 32 35 48
SERTRALINE HCL 51 40 37 26
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on May 10, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.